The letter of J. E. Rosenblatt (6) refutes some published work affirming Blastocystis hominis to be an important agent of intestinal disease in humans. The superb and well-controlled study by Kain et al. is one example of a plethora of sound studies (2) . The proportion of affirmative literature on B. hominis pathogenicity to the "anti" literature is approximately 20:1. The two most quoted "anti" articles are basically flawed. A complete bibliography can be found in an upcoming review by me (11) .
Unfortunately, the scant criticism in the literature of work on the pathogenicity of this protozoan is based on speculation rather than credible data. I submit that ". . . speculation concerning its pathogenicity," as stated by Dr. Rosenblatt, might more accurately be stated ". . . speculation concerning its nonpathogenicity." Dr. (12) . Attachment to or invasion of intestinal mucosa is not a requirement for pathogenicity (as, for example, with Cryptosporidium parvum and Giardia lamblia). However, mucosal invasion in B. hominis infections in gnotobiotic guinea pigs has been recorded (5). As for the requirement for bacterial cohorts for pathogenesis, this is true also of E. histolytica, and this has been in the literature for 35 years (4) .
(iv) Dr. Rosenblatt states that "no antimicrobial agent which is uniquely active against B. hominis has been shown to reliably eradicate both the organism and the diarrhea.
Emetine is very effective against blastocystosis but must be used in the hospital because of possible toxicity. Author's Reply I do not believe the disagreement over the scientific evidence for the pathogenicity of Blastocystis hominis will be settled in the letters section, and I am reluctant to contribute further to this dispute. However, having been given the opportunity to respond to Dr. Zierdt's letter, I will do so. Of course, those interested in this area will recognize that Dr. Zierdt has long been a proponent of the pathogenicity of B. hominis theory. I am simply a detached observer trying to view the question in a scientifically objective way. I am neither in favor of nor against this organism actually being a pathogen.
To support his cause, Dr. Zierdt states that there is a 20:1 preponderance of affirmative literature as compared to "anti" literature concerning pathogenicity. Does he mean that we should base scientific credibility on the quantity of papers written on a subject as opposed to the quality and significance of the content? He also says that ". . . the two most quoted 'anti' papers are basically flawed," without citing the references or indicating how they are flawed.
The second paragraph of Dr. Zierdt's letter seems to suggest that we should assume that B. hominis is a pathogen until it is proven not to be one. Somehow, I always thought that in science things should be the other way around. Since we live in a "sea" of microorganisms, most of which are nonpathogenic for humans, the presence of one of them in our flora should not be equated with pathogenicity. The reference to Entamoeba histolytica is inappropriate since that organism is a well-established pathogen (4) and has been shown to exist in both pathogenic and nonpathogenic forms (5 References 3, 7, and 9 consist of single case histories associating the presence of B. hominis with rectal ulcers, colitis, and ileitis, respectively. Two patients seemed to respond to metronidazole. While there may be a cause-andeffect relationship here, the absence of full microorganism stool workups and the lack of long-term follow-up information on the patients, as well as the dissimilar nature of the lesions in the three patients, leave room for doubt. Perhaps these patients had inflammatory bowel diseases, such as regional enteritis or ulcerative colitis. Moreover, it is very unlikely that the disease in these three patients is representative of the gastroenteritis present in the relatively large number of patients whose stools contain B. hominis when examined in the routine clinical parasitology laboratory. 
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We noted with interest the letters by Rosenblatt (4) and Zierdt (6) concerning the possible pathogenicity of Blastocystis hominis. This discussion is particularly exciting to the microscopist, as B. hominis is probably the second most frequently identified organism (yeasts being the first) in the gut flora. We are concerned that all laboratories are not dealing with the same set of "facts" concerning B. hominis since reports on its prevalence of have varied from 0 (5) to 3.2 (2) to 17.5 (3) %. This may be due in part to differing proficiencies of technologists at recognizing the organism.
When B. hominis was first defined (as an artifact or yeast), the abilities of laboratorians to recognize it varied highly. B. hominis was frequently included in the artifact section of atlases (1) , was never included on proficiency tests, and was hardly ever reported. In recent years it has been included, initially as an optional and then as a required organism, in CAP and other state and national survey samples. The recent review by Zierdt (7) , however, may be the first publication of extensive high-quality photographs of the organism in its various forms and stages. In our experience it is difficult for the untrained microscopist to identify B. hominis with the simple hematology microscope frequently employed for parasite examinations. The frequency of identification improves dramatically when a microscope with high quality optics is employed. Since the organisms lack a cell wall and the cytoplasm is frequently condensed around the periphery, we employ phase-contrast optics as part of every examination. Additionally, we examine all specimens with a trichrome procedure and have found this stain to be excellent for recognition of B. hominis.
Using these procedures we have identified B. hominis with great frequency. At Meadowlands Clinical Laboratory (Rutherford, N.J.), we found an almost 20% positive rate. At Great Smokies Diagnostic Laboratory we found a 15 to 20% positive rate. As both labs are reference laboratories, receiving most of their specimens from patients visiting physician offices, the prevailing complaints are more chronic than acute. In a separate study of patients with acute gastrointestinal complaints from a largely immigrant population (62% Latin American and 23% Asian) visiting the outpatient GI Clinic of Elmhurst Hospital (Bronx, N.Y.), we observed a positive rate of Blastocystis identification of 60% (42 of 70 patients). Trichrome smears were reread at the Centers for Disease Control in Atlanta, Georgia (100% agreement), confirming the accuracy of our observations. It appears to us that this organism is very prevalent in stool samples from both acutely and chronically ill patients and that a need for improved training programs probably exists. We believe that independent of the status of this organism's pathogenicity, its presence should always be reported. Only then will physicians and researchers have the data on which to draw conclusions concerning the organism's medical signficance.
As for the question of pathogenicity, we believe that a certain confusion exists with respect to the possible involvement of this organism in chronic compared with acute illnesses. In 
